..read more

A Novel Combination Therapy Takes an Innovative Approach by Targeting a Key Metabolic Pathway to Block RCC Growth Dr Figlin: Let’s begin by examining some topics related to tumor metabolism and biology and how various factors could play a role in promoting cell growth and proliferation. Please describe the importance of metabolic pathways in kidney cancer and how your work relates to such mechanisms. Dr Whiting:  Metabolism is altered in cancer cells and a lot of oncologists know this from their training, that glucose metabolism in cancer typically is shunted toward production of lactic aci ..read more

GU ASCO 2019 Encapsulating Highlights Through the Lens of a Key Opinion Leader With Insights, Forecasts and Take Home Messages ..read more

Supporting Kidney Cancer Research: Lessons Learned Establishing The Stanford Kidney Cancer Biospecimen Repository Key words: Renal cell carcinoma, biospecimen, repository, biopsy, biology, collection, specimen handling, research protocol, tissue banking, Clinical Research Coordinator. Corresponding Author: John Leppert, Grant S-289, 300 Pasteur Drive, Stanford, CA, 94305 jleppert@stanford.edu Acknowledgements: This manuscript is dedicated to the memory of Larry Lulofs, and to the hundreds of patients with renal cell carcinoma who have selflessly donated their tissues to support our research ..read more

Newsworthy, Late-breaking Information from Web-based Sources, Professional Societies and Government Agencies ..read more

Essential Peer-Reviewed Reading in Kidney CancerMetastatic clear-cell renal cell carcinoma with a long-term response to sunitinib: a distinct pheno­type independently associated with low PD-L1 ex­pression. Kammerer-Jacquet SF, Brunot A, Lefort M, at al. Clin Genitorurin Cancer. 2019 Feb 4; pii: S1558-7673(18)30716-X. doi: 10.1016/j.clgc.2019.01.014. Summary: Long-term responders (LTRs) are defined by at least 18 months of response to sunitinib in metasta­tic clear-cell renal cell carcinoma (ccRCC). The pheno­type of these tumors has never been explored. In a retrospective and multicenter stu ..read more

Kidney Cancer Journal – 2019 – Number 1 EDITOR’S MEMO Remembering Professor Martin Gore, 1951–2019 Tributes pour in, honoring him as ‘force of nature,’ brilliant clinician lthough most of the 4500 or so attendees at this year’s GU ASCO meeting may not have been aware, the death of Professor Martin Gore cast a long shadow over the proceedings for those of us who knew this brilliant clinician and outstanding human being. Dr Gore, 67, one of the UK’s leading oncologists, died in January after experiencing total organ failure following a yellow fever vaccination, an extremely rare complication ..read more

IKCS Recaps Impressive Progress in Ongoing Pivotal Trials and Projects New Directions in Novel Therapeutics Exciting original research was reported at this year’s 17th International Kidney Cancer Symposium (IKCS) in Miami. With “Emerging Concepts and Therapeutic Tri­als in Progress in RCC” as one of the themes for the sessions, the Symposium provided a dynamic venue and a comprehen­sive agenda for more than 300 attendees at this two-day event, one of two international meetings each year sponsored by the Kidney Cancer Association. From early phase clinical trials of novel therapeutics to upd ..read more

ESMO 2018, IKCS Offer Report Cards on New Hypotheses, Real-World Data in RCC Two international conferences within the last three months provided a framework to gain new insights on late-breaking clinical data from pivotal trials and to explore hypothesis-generating results on a broad spectrum of potentially transformational work. This report focuses on selected presentations at the European Society for Medical Oncology (ESMO) 2018 Congress held in Munich and the International Kidney Cancer Symposium held in Miami. ESMO 2018 ESMO 2018 provided a multi-professional platform for oncology educ ..read more

Active Surveillance for Small Renal Masses: Lessons Learned over the Past Decade with a Focus on the DISSRM Registry Phillip M. Pierorazio, MD Associate Professor of Urology and Oncology Department of Urology, The James Buchanan Brady Urological Institute Johns Hopkins University School of Medicine Baltimore, Maryland Introduction Small renal masses (SRM), defined as solid cortical neo­plasms of the kidney less than 4 cm, comprise approxi­mately 40% of all newly diagnosed renal tumors and are most-often detected incidentally when working up an­other medical complaint.1-4 The disco ..read more